BIO BIO.B
← all insidersOpen-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
No open-market insider trades stored for BIO BIO.B in the last 90 days. The full filing history below may still show grants, exercises, or older activity.
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | M | ▼ sell | 1,370→ 1,370 Bio-Rad A Common Stock | — | — | 4,110 | — | — | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | M | ▼ sell | 456→ 456 Bio-Rad A Common Stock | — | — | 1,371 | — | — | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | A | ▲ buy | 4,601→ 4,601 Bio-Rad A Common Stock | — | — | 4,601 | — | — | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | F | ▼ sell | 5040 | $386.11 | $194.6K | 1,232 | −29% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | M | ▲ buy | 1,3700 | — | — | 1,736 | 4.7× | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | F | ▼ sell | 2330 | $386.11 | $90.0K | 366 | −39% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | Mehta Rajat | Officer (EVP, GBL Commercial Operations) | M | ▲ buy | 4560 | — | — | 599 | 4.2× | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▼ sell | 1,152→ 1,152 Bio-Rad A Common Stock | — | — | 2,304 | — | — | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▼ sell | 1,027→ 1,027 Bio-Rad A Common Stock | — | — | 3,083 | — | — | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | A | ▲ buy | 4,313→ 4,313 Bio-Rad A Common Stock | — | — | 4,313 | — | — | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | F | ▼ sell | 4850 | $386.11 | $187.3K | 1,828 | −21% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▲ buy | 1,1520 | — | — | 2,313 | +99% | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | F | ▼ sell | 3690 | $386.11 | $142.5K | 1,161 | −24% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▲ buy | 1,0270 | — | — | 1,530 | 3.0× | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▼ sell | 768→ 768 Bio-Rad A Common Stock | — | — | 1,536 | — | — | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▼ sell | 685→ 685 Bio-Rad A Common Stock | — | — | 2,055 | — | — | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | A | ▲ buy | 2,876→ 2,876 Bio-Rad A Common Stock | — | — | 2,876 | — | — | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | F | ▼ sell | 3050 | $386.11 | $117.8K | 1,652 | −16% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▲ buy | 7680 | — | — | 1,957 | +65% | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | F | ▼ sell | 2460 | $386.11 | $95.0K | 1,189 | −17% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▲ buy | 6850 | — | — | 1,435 | +91% | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | M | ▼ sell | 864→ 864 Bio-Rad A Common Stock | — | — | 1,728 | — | — | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | M | ▼ sell | 1,027→ 1,027 Bio-Rad A Common Stock | — | — | 3,083 | — | — | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | A | ▲ buy | 4,026→ 4,026 Bio-Rad A Common Stock | — | — | 4,026 | — | — | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | F | ▼ sell | 2770 | $386.11 | $107.0K | 3,603 | −7% | −<0.01% (now 0.01%) | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | M | ▲ buy | 8640 | — | — | 3,880 | +29% | +<0.01% (now 0.01%) | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | F | ▼ sell | 3290 | $386.11 | $127.0K | 3,016 | −10% | −<0.01% (now 0.01%) | filing |
| 2026-09-09 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | M | ▲ buy | 1,0270 | — | — | 3,345 | +44% | +<0.01% (now 0.01%) | filing |
| 2026-09-09 | DiVincenzo Jonathan P. | Officer (President & COO) | M | ▼ sell | 1,712→ 1,712 Bio-Rad A Common Stock | — | — | 5,138 | — | — | filing |
| 2026-09-09 | DiVincenzo Jonathan P. | Officer (President & COO) | A | ▲ buy | 6,326→ 6,326 Bio-Rad A Common Stock | — | — | 6,326 | — | — | filing |
| 2026-09-09 | DiVincenzo Jonathan P. | Officer (President & COO) | F | ▼ sell | 6680 | $386.11 | $257.9K | 1,963 | −25% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | DiVincenzo Jonathan P. | Officer (President & COO) | M | ▲ buy | 1,7120 | — | — | 2,631 | 2.9× | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▼ sell | 1,536→ 1,536 Bio-Rad A Common Stock | — | — | 3,072 | — | — | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▼ sell | 1,370→ 1,370 Bio-Rad A Common Stock | — | — | 4,110 | — | — | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | A | ▲ buy | 6,326→ 6,326 Bio-Rad A Common Stock | — | — | 6,326 | — | — | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | F | ▼ sell | 7820 | $386.11 | $301.9K | 4,151 | −16% | −<0.01% (now 0.02%) | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▲ buy | 1,5360 | — | — | 4,933 | +45% | +<0.01% (now 0.02%) | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | F | ▼ sell | 5590 | $386.11 | $215.8K | 3,397 | −14% | −<0.01% (now 0.01%) | filing |
| 2026-09-09 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▲ buy | 1,3700 | — | — | 3,956 | +53% | +<0.01% (now 0.01%) | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▼ sell | 3,455→ 3,455 Bio-Rad A Common Stock | — | — | 6,912 | — | — | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▼ sell | 4,109→ 4,109 Bio-Rad A Common Stock | — | — | 12,330 | — | — | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | A | ▲ buy | 17,251→ 17,251 Bio-Rad A Common Stock | — | — | 17,251 | — | — | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | F | ▼ sell | 1,8540 | $386.11 | $715.8K | 449,019 | −0.4% | −<0.01% (now 1.6%) | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▲ buy | 3,4550 | — | — | 450,873 | +0.8% | +0.01% (now 1.6%) | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | F | ▼ sell | 2,8760 | $386.11 | $1.11M | 447,418 | −0.6% | −0.01% (now 1.6%) | filing |
| 2026-09-09 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▲ buy | 4,1090 | — | — | 450,294 | +0.9% | +0.01% (now 1.6%) | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▼ sell | 1,056→ 1,056 Bio-Rad A Common Stock | — | — | 2,112 | — | — | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▼ sell | 1,027→ 1,027 Bio-Rad A Common Stock | — | — | 3,083 | — | — | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | A | ▲ buy | 4,313→ 4,313 Bio-Rad A Common Stock | — | — | 4,313 | — | — | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | F | ▼ sell | 4700 | $386.11 | $181.5K | 2,025 | −19% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▲ buy | 1,0560 | — | — | 2,495 | +73% | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | F | ▼ sell | 3690 | $386.11 | $142.5K | 1,439 | −20% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▲ buy | 1,0270 | — | — | 1,808 | 2.3× | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | Allison Schwartz | Director | M | ▼ sell | 92→ 92 Bio-Rad A Common Stock | — | — | 185 | — | — | filing |
| 2026-09-09 | Allison Schwartz | Director | M | ▼ sell | 228→ 228 Bio-Rad A Common Stock | — | — | 686 | — | — | filing |
| 2026-09-09 | Allison Schwartz | Director | A | ▲ buy | 719→ 719 Bio-Rad A Common Stock | — | — | 719 | — | — | filing |
| 2026-09-09 | Allison Schwartz | Director | F | ▼ sell | 340 | $386.11 | $13.1K | 1,734 | −2% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | Allison Schwartz | Director | M | ▲ buy | 920 | — | — | 1,768 | +5% | +<0.01% (now <0.01%) | filing |
| 2026-09-09 | Allison Schwartz | Director | F | ▼ sell | 820 | $386.11 | $31.7K | 1,676 | −5% | −<0.01% (now <0.01%) | filing |
| 2026-09-09 | Allison Schwartz | Director | M | ▲ buy | 2280 | — | — | 1,758 | +15% | +<0.01% (now <0.01%) | filing |
| 2026-09-03 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▼ sell | 3,005→ 3,005 Bio-Rad A Common Stock | — | — | 3,005 | — | — | filing |
| 2026-09-03 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▼ sell | 2,082→ 2,082 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-09-03 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | F | ▼ sell | 2,3360 | $380.96 | $889.9K | 446,185 | −0.5% | −<0.01% (now 1.6%) | filing |
| 2026-09-03 | SCHWARTZ NORMAN D | Director, Officer (Chairman & CEO), 10% owner | M | ▲ buy | 5,0870 | — | — | 448,521 | +1% | +0.02% (now 1.6%) | filing |
| 2026-09-03 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▼ sell | 251→ 251 Bio-Rad A Common Stock | — | — | 251 | — | — | filing |
| 2026-09-03 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▼ sell | 174→ 174 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-09-03 | BARRY JAMES | Officer (EVP, President, LSG) | F | ▼ sell | 1540 | $380.96 | $58.7K | 781 | −16% | −<0.01% (now <0.01%) | filing |
| 2026-09-03 | BARRY JAMES | Officer (EVP, President, LSG) | M | ▲ buy | 4250 | — | — | 935 | +83% | +<0.01% (now <0.01%) | filing |
| 2026-09-03 | Allison Schwartz | Director | M | ▼ sell | 75→ 75 Bio-Rad A Common Stock | — | — | 75 | — | — | filing |
| 2026-09-03 | Allison Schwartz | Director | M | ▼ sell | 42→ 42 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-09-03 | Allison Schwartz | Director | F | ▼ sell | 430 | $380.96 | $16.4K | 1,530 | −3% | −<0.01% (now <0.01%) | filing |
| 2026-09-03 | Allison Schwartz | Director | M | ▲ buy | 1170 | — | — | 1,573 | +8% | +<0.01% (now <0.01%) | filing |
| 2026-07-28 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▼ sell | 246→ 246 Bio-Rad A Common Stock | — | — | 492 | — | — | filing |
| 2026-07-28 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | F | ▼ sell | 890 | $314.46 | $28.0K | 503 | −15% | −<0.01% (now <0.01%) | filing |
| 2026-07-28 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | M | ▲ buy | 2460 | — | — | 592 | +71% | +<0.01% (now <0.01%) | filing |
| 2026-05-13 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | S | ▼ sell | 5500 | $246.54 | $135.6K | 346 | −61% | −<0.01% (now <0.01%) | filing |
| 2026-04-28 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▼ sell | 186→ 186 Bio-Rad A Common Stock | — | — | 372 | — | — | filing |
| 2026-04-28 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | F | ▼ sell | 770 | $287.84 | $22.2K | 750 | −9% | −<0.01% (now <0.01%) | filing |
| 2026-04-28 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | M | ▲ buy | 1860 | — | — | 827 | +29% | +<0.01% (now <0.01%) | filing |
| 2026-04-28 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▼ sell | 1,078→ 1,078 Bio-Rad A Common Stock | — | — | 2,156 | — | — | filing |
| 2026-04-28 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | F | ▼ sell | 4200 | $287.84 | $120.9K | 2,564 | −14% | −<0.01% (now <0.01%) | filing |
| 2026-04-28 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | M | ▲ buy | 1,0780 | — | — | 2,984 | +57% | +<0.01% (now 0.01%) | filing |
| 2026-04-23 | PEI MELINDA LITHERLAND | Director | M | ▼ sell | 407→ 407 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-04-23 | PEI MELINDA LITHERLAND | Director | A | ▲ buy | 369→ 369 Bio-Rad A Common Stock | — | — | 369 | — | — | filing |
| 2026-04-23 | PEI MELINDA LITHERLAND | Director | M | ▲ buy | 4070 | — | — | 715 | 2.3× | +<0.01% (now <0.01%) | filing |
| 2026-04-23 | PINKSTON ARNOLD A | Director | M | ▼ sell | 407→ 407 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-04-23 | PINKSTON ARNOLD A | Director | A | ▲ buy | 369→ 369 Bio-Rad A Common Stock | — | — | 369 | — | — | filing |
| 2026-04-23 | PINKSTON ARNOLD A | Director | M | ▲ buy | 4070 | — | — | 715 | 2.3× | +<0.01% (now <0.01%) | filing |
| 2026-04-23 | Hinckley Greg K | Director | M | ▼ sell | 407→ 407 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-04-23 | Hinckley Greg K | Director | A | ▲ buy | 369→ 369 Bio-Rad A Common Stock | — | — | 369 | — | — | filing |
| 2026-04-23 | Hinckley Greg K | Director | M | ▲ buy | 4070 | — | — | 1,215 | +50% | +<0.01% (now <0.01%) | filing |
| 2026-04-23 | EDWARDS JEFFREY L | Director | M | ▼ sell | 407→ 407 Bio-Rad A Common Stock | — | — | 0 | — | — | filing |
| 2026-04-23 | EDWARDS JEFFREY L | Director | A | ▲ buy | 369→ 369 Bio-Rad A Common Stock | — | — | 369 | — | — | filing |
| 2026-04-23 | EDWARDS JEFFREY L | Director | M | ▲ buy | 4070 | — | — | 715 | 2.3× | +<0.01% (now <0.01%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.